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Rational Design and Molecular Diversity for the
Construction of Anti--Bungarotoxin Antidotes
with High Affinity and In Vivo Efficiency
units (see [10] for a recent review). Postsynaptic snake
neurotoxins, like -bgt, bind with high affinity to nAchR
and have been extremely useful in the location of nAchR
ligand sites.
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University of Siena subunits has not yet been solved. However, a sequence
via Fiorentina 1 of  subunit amino-terminal domain, which contains the
I-53100 Siena highly conserved cysteine residues 192 and 193 (se-
Italy quence numbering of 1 subunit from Torpedo electric
organs), was determined as containing at least part of
the nAchR ligand binding site [10, 11]. Synthetic pep-
tides reproducing this sequence of muscle 1 and neu-Summary
ronal 7 nAchR subunits still bind -bgt, albeit with
much lower affinity [12–14].The structure of peptide p6.7, a mimotope of the nico-
Due to lack of information on three-dimensional struc-tinic receptor ligand site that binds -bungarotoxin
ture, mimotopes of the receptor ligand site have essen-and neutralizes its toxicity, was compared to that of
tially been obtained by two different approaches. Anthe acetylcholine binding protein. The central loop of
-bgt binding peptide mimotope, LLPep (with the se-p6.7, when complexed with -bungarotoxin, fits the
quence MRYYESSLKSYPD), was selected from a ran-structure of the acetylcholine binding protein (AChBP)
dom phage library [15] and optimized on the basis of theligand site, whereas peptide terminal residues seem to
peptide-toxin NMR structure to obtain the high-affinitybe less involved in toxin binding. The minimal binding
peptide HAPep (WRYYESSLEPYPD) [16]. In our previoussequence of p6.7 was confirmed experimentally by
study [9], another-bgt binding peptide mimotope (p6.7,synthesis of progressively deleted peptides. Affinity
with the sequence HRYYESSLEPWYPD) of higher affin-maturation was then achieved by random addition of
ity than LLPep was selected by systematic analysis ofresidues flanking the minimal binding sequence and
a synthetic peptide combinatorial library. This was de-by selection of new -bungarotoxin binding peptides
signed on the basis of amino acid sequence comparisonon the basis of their dissociation kinetic rate. The tetra-
branched forms of the resulting high-affinity peptides around C192 and C193 of -bgt binding subunits from
were effective as antidotes in vivo at a significantly different nAchR. Different -bgt binding peptides with
lower dose than the tetra-branched lead peptide. higher binding capacity than those reproducing native
receptor sequences were selected from the peptide
combinatorial library. Among these, p6.7 inhibited -bgtIntroduction
binding to muscle and neuronal receptors with a half-
maximal inhibition constant (IC50) at least 50 times lowerNew drugs can be designed rationally using protein
than that of peptides reproducing native sequences.structural information and molecular modeling. Molecu-
Moreover, a tetra-branched form of p6.7 can protectlar diversity can be constructed by using combinatorial
mice against the lethal effect of the toxin [17].libraries of potentially bioactive molecules. These can
The three-dimensional structures of the complexes ofbe used to empirically “fish” active ligands from a large
-bgt and p6.7 [18], LLPep [19], and HAPep [20, 21]number of structural combinations. Structure-based
respectively were solved and their affinity, and bindingmolecular design and construction of molecular diver-
kinetic constants were compared and analyzed with re-sity are not mutually exclusive, but can be combined to
spect to their NMR structure [22]. A determinant contri-develop specifically targeted drugs.
Peptide libraries, expressed on phages or obtained bution for understanding the three-dimensional organi-
by solid-phase synthesis [1, 2], can be used to select zation of nAchR ligand sites came from the crystal
specific sequences, named mimotopes, which, although structure of the acetylcholine binding protein (AChBP)
different from native sequences, can mimic structural [23, 24]. AChBP is a soluble homopentameric transmitter
and functional features of domains of proteins [3, 4]. receptor, structurally and functionally related to the
Mimotopes can reproduce protein recognition surfaces, amino-terminal domain of nAchR  subunits containing
like those involved in antigen-antibody [5, 6] or ligand- the ligand site, and binds several nicotinic ligands, in-
receptor recognition [7, 8]. This property gives them cluding -bgt. The sequence similarity of AChBP and
useful diagnostic and therapeutic applications. nAchR  subunits makes it possible to locate AChBP
In a previous paper we described the production of ligand sites on loops at interfaces between each subunit.
peptide mimotopes of the -bungarotoxin (-bgt) bind- The structure of AChBP homopentamer and its ligand
ing site of nicotinic acetylcholine receptors (nAchR) [9]. binding sites is presently the most reliable model for
Nicotinic receptors are ligand-gated ion channels com- studying nicotinic receptor binding sites, and it has al-
posed of five homologous, membrane-spanning sub- ready been compared with the structures of the mimo-
tope peptide HAPep [21] and of two cognate peptides,
reproducing the 178–196 and the 182–202 sequence*Correspondence: braccil@unisi.it
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Table 1. p6.7 Sequence Alignment with 1 Peptide and the
Putative Binding Loop of AchBP
Sequence PDB ID Alignment
1 14
p6.7 1JBD HRYYESSLEPWYPD
1 1L4W RGWKHWVYYTCCPDTPYLDIT
182 202
1 14
p6.7 1JBD HRYYESSLEPWYPD
AChBP 1I9B TQKKNSVTYSCCPEA-YEDVE
177 196
Stretches showing the best three-dimensional superposition are
highlighted in bold, with a calculated rmsd of 1.50 and 1.32 A˚ for
1 and AChBP, respectively.
of the neuronal 7 [25] and muscle 1 [26] subunit,
respectively.
In the present study, we compared the structure of
the peptide mimotope p6.7 with that of homologous
sequences from AChBP and the 1 peptide described
in [26]. Structural information was used in association
with kinetic binding data, obtained by surface plasmon
resonance (SPR) on progressively deleted p6.7. This
provided information on the essential toxin binding re-
gion of p6.7. Affinity maturation of the peptide was then
obtained by random addition of residues flanking the
minimal binding sequence, followed by empirical selec-
tion of new binding sequences on the basis of their
dissociation kinetic rate constant (koff).
A tetra-branched dendrimer of a high-affinity peptide
obtained by this procedure is more effective for in vivo
neutralization of -bgt toxicity than the tetra-branched
p6.7, and more active than any other analogous peptide
mimotope described so far.
Results and Discussion
Comparison of p6.7 with Structural Models of the
Nicotinic Receptor Binding Site
The three-dimensional structure of -bgt-bound p6.7
(PDB ID 1JBD) [18] was compared to that of a 21-mer
peptide reproducing the 182–202 sequence of the 1
subunit of nicotinic receptor from Torpedo electric or-
gans (RGWKHWVYYTCCPDTPYLDIT, PDB ID 1L4W)
[26] when bound to the same toxin, to obtain a good
rmsd (1.50 A˚) using the maximum number of residues
(Figure 1A). The best superposition was found for resi-
dues 189–196 and 3–10 of 1 peptide and p6.7 respec-
tively, giving an rmsd of 1.50 for backbone atoms (Table
1). The region showing good structural agreement was
that of the central loop carrying tyrosine 190 and cys-
teines 192 and 193 of 1 peptide. The turn region of
peptide p6.7 showed a high structural similarity to that
(B) Structural superposition of p6.7--bgt complex (PDB ID 1JBD)
Figure 1. Comparison of p6.7 with Structural Models of the Nicotinic on putative ligand binding loop of AChBP (PDB ID 1I9B): close view
Receptor Binding Site of the backbone fitting result for residues 3–10 of p6.7 on residues
(A) Structural superposition of p6.7 from -bgt/p6.7 complex (PDB 184–191 of AchBP. Toxin R36 is stacking onto AChBP W143. Struc-
ID 1JBD) on 1 (182-202)--bgt complex (PDB ID 1L4W). Structures tures of toxin and peptide are colored green and yellow, respec-
of the toxin and 1 peptide in bound form are colored blue and tively; AChBP is colored blue.
cyan, respectively; p6.7 is colored yellow. (C) Toxin-AChBP complex as viewed down the oligomer 5-fold axis.
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of the native sequence when bound to -bgt. In both different peptides were synthesized reproducing the
14-mer sequence H1RYYESSLEPWYPD14, progressivelycases, the loops matched the key region of interaction.
The same procedure was repeated to overlay the shortened at the N- and C termini. Peptides were then
analyzed for -bgt binding by injecting them over astructure of -bgt-bound p6.7 on the homologous se-
quence of the loop of AChBP from Lymnaea stagnalis BIACORE flow cell, where biotinylated -bgt had pre-
viously been captured by streptavidin.[23, 24], which contains the putative AChBP ligand site
(PDB ID 1I9B) (Figures 1B and 1C). A backbone rmsd Regarding peptides shortened at the N terminus, the
13-mer peptide showed a sharp drop in binding,of 1.32 A˚ was obtained for stretches 3–10 and 184–191
of the peptide and protein respectively (Table 1). Again, whereas peptides lacking both H1 and R2 positions did
not bind -bgt (Figure 2A). When peptides shortened atthere is a very good three-dimensional structural agree-
ment between the central turns of p6.7 and of the native the C terminus were studied, it was found that those
shorter than 11-mer did not bind -bgt (Figure 2B). Theprotein.
Superposition of the peptide of the -bgt/p6.7 com- minimal essential binding sequence was therefore
R2YYESSLEPW11, which is in good agreement with re-plex on the loop of AChBP gave another interesting
result. Assuming that peptide and protein loop interact sults obtained by structure-based comparison of p6.7
with models of the nicotinic receptor binding sites (Ta-in the same way, a hypothetical model of the -bgt/
AChBP complex can be obtained. Superposition showed ble 1).
that toxin loops 1 and 2 and the C terminus region fit
the AChBP surface, with no Van der Waals violations Systematic Affinity Maturation
of the Peptide Mimotopegreater than 0.60 A˚ for backbone atoms, but three of
approximately 1 A˚. A model of interaction between -bgt In an attempt to obtain an increase in -bgt binding
affinity with respect to the original p6.7 peptide, an itera-and nicotinic receptors can therefore be obtained (Fig-
ures 1B and 1C). The model was also compared to that tive process was carried out. Structural analysis of p6.7
and progressive shortening of peptide sequence re-previously proposed in [21] between the same AChBP
and -bgt/HAPep complex (PDB ID 1HC9), which we spectively indicated peptide sequences 3–10 and 2–11
as essential for binding. On this basis, positions 1, 12,reconstructed from the PDB structure files, following
the fitting procedure reported on the paper. Our model 13, and 14 of the peptide sequence, one at a time, were
systematically redefined, introducing each of the 19confirms the geometry of the complex proposed in [21],
which differs only for the presence of more backbone L-amino acids (C was omitted to avoid thiol oxidation).
Peptide binding to -bgt was analyzed by BIACORE,clashes (six Van der Waals violations greater than 0.60 A˚,
three greater than 1 A˚, and one greater than 2 A˚). and sequences were selected on the basis of their koff.
Ranking of peptide koff by BIACORE is fast and can beIn the AChBP crystal structure [24], an acetylcholine
binding site was identified, indeed, by the presence of a done in a single run, using unlabeled crude peptide
samples. It is therefore particularly suitable for sequenceN-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid
(HEPES) positively charged buffer molecule situated in selection from peptide libraries.
Analysis of peptide--bgt binding showed that the 11-a cleft underneath the aforementioned loop and making
a cation- interaction with W143, as expected for nico- mer peptide with F in position 1 had the lowest koff (1.05
103 s1), lower than the 11-mer peptide with H (liketinic agonists [27, 28]. Such residue is also conserved
in Torpedo nAchR  subunit sequence (W149). Interest- the original peptide p6.7) in this position. F was then
selected in position one, and the iterative process wasingly, in our model the HEPES molecule is replaced by
-bgt R36 guanidinium group, which makes a cation- repeated to define position 12. Peptides with D or P in
this position had the lowest koff.interaction with the same W143 (see Figure 1B), sug-
gesting a general mechanisms for receptor binding by Since the selected F1RYYESSLEPWD12 and F1RYYES
SLEPWP12 peptides were found to have similar koff (7 acetylcholine mimics. Such observation confirms the
findings reported in [21] and those recently reported 104s1 and 8 104s1, respectively) both were used to
construct further 13-mer sublibraries. From the results ofin [26] and [29], based on a combination of homology
modeling and NMR structure reconstruction of the peptide koff analysis of these sublibraries, peptides with
D in position 13 were selected. The addition of anotherthree-dimensional structure of AchR extracellular do-
D in position 14 produced a further decrease in koff (2 main in complex with -bgt and -cobratoxin, respec-
104s1) of the 13-mer peptide with D12 (3.1  104s1)tively. The authors proposed this cation- interaction
(Figure 3).as general mechanisms for receptor binding by acetyl-
Affinity maturation of the lead p6.7 peptide enabledcholine mimics.
new sequences, quite different from receptor native se-
quences, to be selected. Although Y12 corresponds to
Definition of the Minimal Essential Residues a highly conserved residue in -bungarotoxin binding
for p6.7--bgt Binding receptors, its replacement in the p6.7 sequence resulted
Structural comparison of the complexes formed by in an increase in toxin binding. In peptides with the
-bgt with p6.7, and with structures that can be taken lowest koff, Y12 is replaced by D or P, both having signifi-
as models of the nicotinic receptor ligand site, indicated cant chemical differences from the aromatic residue of
that the central loop of p6.7 is the main interacting struc- the native sequence. However, structural studies and
ture, whereas peptide terminal residues seem to be less empirical definition of p6.7 minimum binding sequence,
involved in toxin binding. both excluded Y12 from the main peptide interacting
structure.In order to confirm critical residues for -bgt binding,
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Figure 2. Definition of p6.7 Minimal -bgt Binding Sequence
-bgt binding of peptide from p6.7 sequence, progressively shortened at N- (A) and C (B) termini, was analyzed by BIACORE on -bgt-biotin
SA sensor chip. Peptide concentration was 10 g/ml, flow rate 10 l/min.
Association and dissociation kinetic rates (kon and koff synthesized in a tetra-branched multiple antigen peptide
(MAP) form and tested for their ability to inhibit -bgtrespectively) and affinity constants (KA) of the selected
13-mer and 14-mer peptides, having the sequences binding to nAchR, in vitro and in vivo.
We compared -bgt binding capacity of MAPs withF1RYYESSLEPWDD13 (13-merDD) and F1RYYESSLEPW
DDD14 (14-merDDD), respectively, were calculated from those of the respective monomeric peptides. As we ob-
served in [17], tetrameric peptides retained the functionalBIACORE sensorgrams obtained at different peptide
concentrations, and compared with those of the original properties of the corresponding monomeric peptides in
vitro, with nearly identical KA and IC50.peptide mimotope p6.7. The 14-merDDD peptide had a
KA (1  108 M1) ten times that of the peptide p6.7, Kinetic rates and affinity of toxin binding sites of MAP
peptides were calculated by immobilizing biotin-labeledessentially determined by the 1 log decrease in the koff
(Figure 4). tetra-branched peptide on a streptavidin-coated BIA-
CORE SA sensor chip, using -bgt as analyte in solution,
in order to avoid multivalent binding [17]. The KA resultsIC50
The half-maximal inhibition constant IC50 was calculated were 9.46  107 for MAP413-merDD and 1.9  108 for
MAP414-merDDD. IC50, calculated by competition RIA,for 13-merDD and 14-merDDD peptides by a solid phase
radioimmunoassay using 125I--bgt and affinity-purified results were 1.4 109 M for MAP413-merDD and 0.97
109 M for MAP414-merDDD.nAchR from Torpedo electric organs and was one tenth
that of peptide p6.7, in line with their different affinities We tested the ability of the selected tetrameric 13-
merDD and 14-merDDD peptide to neutralize -bgt lethal-(Figure 5). The IC50 of the 14-merDDD peptide (2.5 nM)
is analogous to the IC50 of the previously described ity in vivo. To compare the in vivo activity of monomeric
and tetrameric peptides, mice were injected subcutane-HAPep [16].
ously with 10 g of -bgt, and after 5 min, they were
given tetrameric or monomeric peptides. The tetramericIn Vitro and In Vivo Activity of High-Affinity MAPs
The tetrameric p6.7 peptide proved to be an effective peptides were highly effective in neutralizing the lethality
of the toxin, whereas the monomeric peptides were inef-antidote against -bgt at a dose of 100 g/mouse. Al-
though the monomeric peptide had the same KA and fective, even when used at five times the dose of the
corresponding tetra-branched peptides.IC50, it was ineffective in vivo, even at a dose ten times
that of the corresponding tetrameric peptide [17]. Se- Since the 13-merDD and 14-merDDD MAPs showed
very similar protective activity against -bgt toxicitylected 13-merDD and 14-merDDD peptides derived from
affinity maturation of the lead p6.7 peptide, were then when tested at different concentrations on a small popu-
Figure 3. Affinity Maturation of p6.7
Peptides koff ratio with respect to p6.7 is
shown. Peptides diluted to 10 g/ml were
injected at 10 l/min over -bgt-biotin SA
sensor chip; flow rate was 10 l/min. Peptide
koff were calculated with BIAevaluation 3.0
software.
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Figure 4. Comparison of -bgt Binding of
p6.7 and Selected 13-merDD and 14-merDDD
Peptides
Peptides at concentrations ranging from 0.1
to 10 g/ml were injected over -bgt-biotin
SA sensor chip. Flow rate was 10 l/min. Ki-
netic rates and affinity constants were calcu-
lated by BIAevaluation 3.0 software. The
overlay of sensorgrams obtained with 2 g/
ml is reported in the figure.
lation of animals, we chose to test only the 14-mer MAP, effective in vivo (2.5 mg per mouse) [30]. Cyclization
is a well-known strategy to confer in vivo stability towhich seemed slightly more effective at low concentra-
tions, on a larger population. The results are reported peptides, and this, more than an increase in affinity,
might have been responsible for the increased in vivoin Table 2. Using the 14-merDDD peptide, injection of
100 g monomeric peptide did not protect mice from efficiency of the cyclic peptide.
The in vivo efficiency of branched peptides with re-the effect of the toxin, since all died in about 1 hr. A
dose of 5 g MAP produced a 2.5–5 hr delay in the lethal spect to the corresponding monomeric forms, was
shown previously [17]. The increased in vivo activity ofeffect, whereas a 10 g sample of MAP protected 25%
of the mice from toxin lethality. Five out of twenty mice the here described high affinity MAPs with respect to
the lead tetrameric p6.7 peptide reflects, indeed, theinjected with 10 g MAP survived with no symptoms,
seven mice died in 5–7 hr, seven died in about 24 hr, difference in affinity and IC50 of the new mimotope pep-
tides.and one survived for 48 hr. Injection of 20 g MAP
completely neutralized -bgt lethality in mice. This result opens new perspectives that go beyond
use of our high-affinity peptide mimotopes as syntheticDespite the increase in affinity with respect to the lead
peptide p6.7, neither the 13-merDD nor the 14-merDDD antidotes against snake neurotoxin.
monomeric peptide induced protection against -bgt
lethality in mice, at a dose of 100g. This is in agreement Significance
with what already reported for HAPep, which having the
same IC50 as the 14-merDDD conferred protection from Structural comparison of the complex of -bgt with
the peptide mimotope of the nicotinic receptor ligand-bgt only at a dose of 5 mg per mouse [16]. A cyclic
peptide, derived from the LLPep [15], and with a higher binding site, p6.7, with available structural models for
the nicotinic receptor neurotoxin binding site allowedaffinity than LLPep itself, although showing a higher
IC50 (12 nM) with respect to HAPep, results were more defining of the putative critical interaction region of
Figure 5. Inhibition of 125I--bgt Binding to
Torpedo nAchR by p6.7, 13-merDD, and 14-
merDDD
Peptides at different concentrations, ranging
from 5 M to 50 fM, were incubated with 105
cpm of 125I--bgt (Amersham Italia Srl) for 1
hr at room temperature on plates coated with
affinity-purified nAchR. Assays were per-
formed in triplicate and the half-maximal inhi-
bition constant IC50 was calculated by nonlin-
ear regression analysis using GraphPad
Prism 3.02 software.
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Table 2. In Vivo Activity of Monomeric and Tetrameric Peptides
Amount (g)a
Monomeric MAP4 Monomeric
No. of Mice -bgt 13-merDD 13-merDD 14-merDDD MAP4 14-merDDD Outcomeb
14 10 - - 0 0 14 dead after 28  3c min
3 10 - - 100 0 3 dead after 59  3c min
11 10 - - 0 5 11 dead after 220  68c min
20 10 - - 0 10 5 alive
7 dead after 389  64c min
7 dead after 1291 142c min
1 dead after 2880 min
12 10 - - 0 20 12 alive
3 10 100 0 - - 3 dead after 48 min  2c
3 10 0 5 - - 3 dead after 50 min  10c
3 10 0 10 - - 2 alive
1 dead after 180 min
5 10 0 20 - - 5 alive
a Subcutaneous injection.
b Treated mice were followed for 10 days.
c Standard deviation.
nyl chemistry and O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluro-the peptide. This information was confirmed experi-
nium hexafluorophosphate/1,3-diisopropylethylamine activation.mentally by progressive deletion of peptide terminal
MAPs were synthesized on Fmoc4-Lys2-Lys-	Ala Wang resin.residues, which enabled definition of the minimal es-
Side chain protecting groups were tert-butyl ester for D and E;
sential binding sequence. On this basis, affinity matu- trityl for H, N, and Q; tert-butoxycarbonyl for K and W; 2,2,4,6,7-
ration of the lead p6.7 peptide mimotope was obtained pentamethyldihydrobenzofuran-5-sulfonyl for R; and tert-butyl ether
for S, T, and Y.by randomization of residues flanking the minimal
Peptides were then cleaved from the resin and deprotected bybinding sequence and direct functional selection of
treatment with trifluoroacetic acid containing water and triisopropyl-new peptides according to koff. A peptide mimotope
silane (95/2.5/2.5).that binds -bgt with almost ten times the affinity of
Crude peptides were purified by reversed-phase chromatography
the lead peptide p6.7 was obtained. Moreover, the on a Vydac C18 column. Identity and purity of final products was
tetra-branched form of the resulting high-affinity pep- confirmed by electrospray (ESI) or matrix-assisted laser desorption
ionization (MALDI) mass spectrometry.tide was effective as antidote in vivo at a significantly
lower dose than the tetra-branched lead peptide. In
SPR Experimentsconclusion, structural-based design combined with
SPR measurements were performed on a BIACORE 1000 Upgradedconstructed molecular diversity and functional selec-
(BIACORE AB, Uppsala, Sweden). Biotin-conjugated--bgt was im-
tion, made it possible to develop a specifically targeted mobilized on a streptavidin-coated SA-sensor chip. For dissociation
peptide ligand of high affinity. kinetic rate ranking, peptides diluted to 10 g/ml in HEPES buffer
saline (HBS) (10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.005%We recently demonstrated that some of the prob-
polysorbate 20, pH 7.4) were injected at a flow rate of 10 l/minlems related to the low activity of synthetic peptides
over -bgt. To calculate kon, koff, and KA, purified peptides, dilutedin vivo can be overcome by synthesis of branched
in HBS at concentrations ranging from 0.1–10 g/ml, were used.peptides [17]. This result is confirmed in the present
Alternatively, biotinylated monomeric or tetra-branched peptides
study, where the tetra-branched peptide bioactivity were immobilized on a streptavidin-coated SA-sensor chip and
fully reflects the increase in affinity, whereas the mo- -bgt, diluted at different concentration in HBS, was injected at a
flow rate of 10 l/min over each peptide.nomeric peptide bioactivity does not. Branched pep-
kon, koff, and KA were calculated using the BIAevaluation 3.0tides have a clear pharmacological advantage over
software.linear monomeric peptides, an advantage unrelated to
the possibility of multimeric binding, but probably to
Radioimmunoassay
a different clearance and resistance to proteolysis. RIA competition experiments were performed on microtiter plates
This can increase the in vivo therapeutic and diagnos- (Falcon 3912; Becton Dickinson, Oxanan, CA) coated over night at
4
C with affinity purified nAchR from Torpedo electric organs [32]tic use of peptides specifically directed to soluble (like
(5 g/ml in 0.05 carbonate buffer [pH 9.6]) and then blocked withtoxin from certain pathogens) and extracellular (like
3% BSA in phosphate buffer saline (PBS) (pH 7.4) for 1 hr at roommembrane tumor antigens) targets.
temperature. Peptides at concentrations ranging from 5 M to 50
fM were incubated with 105 cpm of 125I--bgt (Amersham Italia Srl)
Experimental Procedures for 1 hr at room temperature. After washing with PBS, -bgt binding
to nAchR was detected by a -counter.
Structural analyses and graphical representations were realized with The half-maximal inhibition constant IC50 of each peptide was
MolMol Software [31]. evaluated by nonlinear regression analysis of curves using
GraphPad Prism 3.02 software.
Peptide Synthesis
Monomeric peptides were synthesized as peptide amides by an In Vivo Experiments
automated synthesizer (MultiSynTech, Witten, Germany) on a Rink For these experiments, 15 g Swiss mice were inoculated subcutane-
ously (s.c.) with 10 g -bgt (SIGMA) in 100 l PBS (pH 7.4), andAmide MBHA resin (Nova Biochem) using 9-fluorenylmethoxycarbo-
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after 5 min they were inoculated s.c. with different amounts of mono- receptor: analysis using a phage-epitope library. Proc. Natl.
Acad. Sci. USA 94, 6054–6058.meric or MAP peptides in 250 l PBS (pH 7.4). Mice treated with
peptide antidotes were followed for 10 days. 16. Kasher, R., Balass, M., Scherf, T., Fridkin, M., Fuchs, S., and
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